Trevi Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(13,192) | $(10,340) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 2,191 | 1,208 |
| Operating lease right-of-use assets | 105 | 112 |
| Depreciation and amortization | 34 | 37 |
| Accretion of available-for-sale marketable securities, net | (431) | (395) |
| Changes in operating assets and liabilities: | ||
| Accrued expenses and other liabilities | (1,075) | (1,501) |
| Accounts payable | (1,483) | (1,993) |
| Prepaid expenses and other current assets | (2,838) | (605) |
| Net cash used in operating activities | (16,689) | (13,477) |
| Investing activities: | ||
| Proceeds from maturities of available-for-sale marketable securities | 25,552 | 17,595 |
| Purchases of available-for-sale marketable securities | (8,485) | (27,546) |
| Purchases of property, equipment and leasehold improvements | (102) | — |
| Net cash provided by (used in) investing activities | 16,965 | (9,951) |
| Financing activities: | ||
| Proceeds from exercises of stock options | 222 | 718 |
| Proceeds from exercises of warrants | — | 8,220 |
| Payments of offering costs | — | (222) |
| Payments of finance lease | — | (11) |
| Net cash provided by financing activities | 222 | 8,705 |
| Net increase (decrease) in cash and cash equivalents | 498 | (14,723) |
| Cash and cash equivalents at beginning of period | 18,914 | 34,097 |
| Cash and cash equivalents at end of period | $19,412 | $19,374 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.